Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The DNA-dependent activator of IFN-regulatory factors (DAI), also known as ZBP1 or DLM-1, is a cytosolic DNA sensor that detects foreign DNAs, including B-DNA and Z-DNA conformations, through its N-terminal Zα, Zβ, and D3 DNA-binding domains to initiate innate immune responses. Upon binding, DAI undergoes conformational changes, activates IRF3 and NF-κB signaling pathways, and promotes type I interferon production and antiviral cytokine expression, while also associating with RIPK3 to trigger PANoptosis, an inflammatory programmed cell death. In immune cells like macrophages, DAI senses self-apoptotic DNA, driving M2b polarization via calcium signaling, which contributes to pathological inflammation. Elevated DAI expression is observed in systemic lupus erythematosus (SLE) patients and lupus models, where it exacerbates lupus nephritis by amplifying autoimmune responses. Knockdown or blockade of DAI ameliorates SLE symptoms by inhibiting macrophage activation and inflammation, positioning it as a potential therapeutic target, though no approved drugs currently target it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA-dependent activator of IFN-regulatory factors (DAI) (DAI).